Therefore, our study suggests that DANCR is an oncogenic lncRNA that promotes neuroblastoma progression via the DANCR/miR-125a-5p/ABL2 axis, which may serve as a novel prognostic biomarker and therapeutic target for neuroblastoma. The gene discussed is DANCR; the disease is neuroblastoma.